NICOTINAMIDE mononucleotide (NMN), a molecule touted for its anti-ageing potential, has been listed as a permissible ingredient by the Therapeutic Goods Administration (TGA) for use in Australian therapeutic goods.
NMN is a naturally occurring molecule made by the body that helps it replenish NAD levels, which are essential for energy production and DNA repair, with some research suggesting it may also help improve insulin sensitivity and heart function.
Production of NMN decreases with age, but taken as an oral supplement, appears to support NAD production.
Earlier this year, the TGA issued a safety alert stating NAD and NMN were not permitted ingredients in Australia, and medicines that made claims about them through their name, labelling or advertising were at risk of breaching the law.
The Australian biotechnology company behind the regulatory change, Longevity Life Sciences (LLS), is currently the only company permitted to supply the product as CellVive NMN for human use in Australia.
Associate Professor Sophie Stocker of the University of Sydney Pharmacy School, who is on the LLS Scientific and Advisory Board, said, "Regulation is essential because any health claim must be backed by solid evidence".
"Early research shows promising signals, but regulators ensure those signals are translated into claims that match the level of proof available and protect consumers from misinformation," she explained.
"With continued rigorous clinical studies, NMN's role in supporting healthy aging is becoming clearer, and emerging evidence suggests it may have additional benefits for metabolic and physiological health - though the potential beyond ageing is still being properly explored and validated," Assoc Prof Stocker cautioned.
The above article was sent to subscribers in Pharmacy Daily's issue from 12 Dec 25
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 12 Dec 25
